Minaris Advanced Therapies Executive and Leadership Team

Orla Cloak, the Chief Executive Officer at Minaris Advanced Therapies, directs the overarching corporate strategy and global vision. Cloak guides the organization's expansion in the gene and cell therapy manufacturing sector, leveraging over 25 years of industry experience. This leadership role involves setting strategic priorities, fostering key client relationships, and ensuring the company's commitment to advancing cell therapy excellence. Overseeing all major business units, Orla Cloak drives the company's mission to provide high-value clinical and commercial manufacturing services and development solutions. The Chief Executive Officer's focus remains on innovation and state-of-the-art facility operations across Japan, Germany, and the United States, solidifying Minaris's position as a leading GMP contract manufacturing organization.

William Burckardt, the Chief Financial Officer at Minaris Advanced Therapies, oversees all financial planning, reporting, and capital management activities. Burckardt ensures the financial health and strategic allocation of resources to support the company's global expansion and investment in state-of-the-art manufacturing facilities. This executive function is critical for sustaining high-value clinical and commercial services for over 180 clients. Driving financial strategy and optimizing profitability, William Burckardt plays a key part in the company's long-term growth trajectory. The Chief Financial Officer's responsibilities include managing investor relations, budgeting, and ensuring fiscal compliance across all international operations. Burckardt's financial acumen is essential for Minaris's continued success as a leading GMP contract manufacturing organization.

Darwin Richardson, the Chief Operating Officer at Minaris Advanced Therapies, manages the day-to-day operational execution and global manufacturing network. Richardson oversees the seamless integration of development, GMP manufacturing, and analytical services across all facilities in Japan, Germany, and the United States. This leadership position is crucial for ensuring high-value clinical and commercial production for a diverse client base. Driving operational efficiency and quality assurance, Darwin Richardson ensures adherence to stringent regulatory standards. The Chief Operating Officer's responsibilities include optimizing supply chain logistics and resource allocation to support the company's rapid growth and commitment to advancing cell therapy excellence. Richardson's operational oversight directly supports Minaris's mission to be a premier contract manufacturing organization.

Hiroto Bando, the President (Japan) at Minaris Advanced Therapies, leads the strategic direction and operational execution for the company's Japanese market. Bando ensures the seamless delivery of gene and cell therapy manufacturing services, aligning with global standards and local regulatory requirements. This leadership role is instrumental in expanding Minaris's footprint and client base within Japan. Overseeing all regional operations, Hiroto Bando drives growth and innovation, reinforcing the company's commitment to advancing cell therapy excellence. The President (Japan)'s focus includes fostering strong relationships with local partners and clients, ensuring the state-of-the-art facilities in Japan contribute significantly to the company's overall mission. Bando's leadership strengthens Minaris's position as a key player in the Asian therapeutic manufacturing landscape.

Shinobu Kuwae, the Chief Technology Officer at Minaris Advanced Therapies, architects the company's technological roadmap and innovation pipeline. Kuwae spearheads the development and implementation of cutting-edge manufacturing technologies essential for gene and cell therapies. This critical role ensures that Minaris maintains its leadership in providing advanced development solutions and GMP manufacturing capabilities. Overseeing research and development initiatives, Shinobu Kuwae drives the integration of novel processes and analytical services to support over 180 therapeutic clients. The Chief Technology Officer's expertise is pivotal in enhancing the efficiency and scalability of manufacturing operations, directly contributing to the company's global impact and commitment to therapeutic innovation.

Prakash Manwani, the Chief Information Officer at Minaris Advanced Therapies, directs the company's information technology strategy and digital infrastructure. Manwani ensures robust and secure IT systems that support complex gene and cell therapy manufacturing processes and global client collaboration. This role is vital for maintaining operational continuity and data integrity across all international sites. Overseeing the implementation of advanced digital solutions, Prakash Manwani enhances efficiency and data management capabilities. The Chief Information Officer's focus includes cybersecurity, system integration, and leveraging technology to streamline development and manufacturing services. Manwani's strategic IT leadership is fundamental to Minaris's ability to deliver innovative solutions and maintain its competitive edge in the therapeutic sector.

Rikisha Collins, the Chief Legal Officer & General Counsel at Minaris Advanced Therapies, provides strategic legal counsel and oversees all corporate governance and compliance matters. Collins ensures that all operations, particularly in GMP contract manufacturing and development services, adhere to global regulatory frameworks and industry best practices. This critical role safeguards the company's interests and mitigates legal risks across its international presence in Japan, Germany, and the United States. Managing all legal affairs, Rikisha Collins supports business development and client agreements, ensuring robust contractual frameworks. The Chief Legal Officer & General Counsel's expertise is vital for navigating the complex legal landscape of the therapeutic sector and upholding Minaris's commitment to excellence and innovation.